Open an account

Intensity Therapeutics

INTS · NASDAQ

$3.28−$0.01 (−0.30%)TodayMarket closed ·
Prev close $3.29

About INTS

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Employees
5
Headquarters
Shelton, Connecticut
Listed
Jun 30, 2023
Sector
Health Care
Industry
Biotechnology
Website
intensitytherapeutics.com

INTS key statistics

Market cap
10.74M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
22.96K
Volume
2.60K
Open price
$3.27
High today
$3.31
Low today
$3.25
52 Week high
$43.50
52 Week low
$3.10

Intensity Therapeutics (INTS) at a glance

As of Oct 20, 2026, Intensity Therapeutics (INTS) shares are priced at $3.28, giving the company a market cap of 10.74M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.25 and $3.31. The current price is 0.9% above the day's low and 0.9% below its high.

Volume so far is 2.60K shares, below the average of 22.96K shares a day.

Over the past year Intensity Therapeutics has ranged from $3.10 to $43.50, and now sits 0% of the way up that range.

Intensity Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.11 per share against an estimate of -$0.89.

The average analyst price target is $17.54, 434.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $17.54
Low
$7.07
Now
$3.28
High
$33.60

INTS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 21.0% on average.

  1. Q3 FY24: reported -$6.25 per share against an estimate of -$7.78
  2. Q4 FY24: reported -$5.50 per share against an estimate of -$5.71
  3. Q1 FY25: reported -$5.50 per share against an estimate of -$4.97
  4. Q2 FY25: reported -$3.25 per share against an estimate of -$5.04
  5. Q3 FY25: reported -$1.50 per share against an estimate of -$2.23
  6. Q4 FY25: reported -$1.31 per share against an estimate of -$1.27
  7. Q1 FY26: reported -$0.96 per share against an estimate of -$1.11
  8. Q2 FY26: reported -$1.11 per share against an estimate of -$0.89

INTS news

  • Press releasePRNewswire

    Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseGlobe Newswire

    NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

  • Press releasePRNewswire

    Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

  • Press releasePRNewswire

    Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

  • Press releasePRNewswire

    Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

  • Press releasePRNewswire

    Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

  • Press releasePRNewswire

    Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.